CHINA’S CANSINO DEFENDS COVID-19 VACCINE CANDIDATE AFTER EXPERTS CAST DOUBT
China’s CanSino Biologics said on Wednesday (Sept 9) that expert opinion on its high-profile COVID-19 vaccine candidate should not be followed “blindly” without sufficient clinical trial data.
Scientists outside the company have expressed concern that the effectiveness of CanSino’s candidate Ad5-nCoV, which is based on a common cold virus to which many people have been exposed, could be limited.
They said existing antibodies against the common cold virus might undermine Ad5-nCoV.
“Vaccine development is a practice-based science, and we should not blindly follow experts,” Zhu Tao, chief scientific officer.